UCB, a global biopharmaceutical company, announced it will present 26 abstracts from its epilepsy portfolio at the upcoming International Epilepsy Congress (IEC) in Lisbon, Portugal, from August 30 to September 3, 2025.

The data spans developmental and epileptic encephalopathies such as Dravet syndrome and Lennox-Gastaut syndrome, as well as prolonged seizures, seizure emergencies, and early pipeline research. The presentations underline UCB’s continued investment in neurology research and the company’s broader commitment to building a strong pipeline that will shape future pharmaceutical manufacturing needs.

Dimitrios Bourikas, global epilepsy medical head of DEE and Epilepsy at UCB, said the breadth of data reflects the company’s focus on advancing innovative solutions that address real-world patient needs, with the goal of improving outcomes and shaping a better future for those living with epileptic conditions.

By driving research that connects disease insights with practical treatment outcomes, UCB is reinforcing its long-term strategy of scaling novel therapies from development to large-scale manufacturing. This approach positions the company to deliver next-generation epilepsy treatments while enhancing its manufacturing capabilities to support global demand.

Based in Brussels, Belgium, UCB continues to focus on the discovery, development, and future production of innovative medicines to transform the lives of people with severe central nervous system and immune system diseases.